Ceftriaxone (Ro 13-9904), a newly developed cephalosporin with a long halflife, was evaluated for efficacy and safety in 19 patients with serious infections. Underlying illnesses were present in 16 patients. Ceftriaxone was given intravenously every 12 h. Infections treated included gram-negative bacillary pneumonias (two cases), staphylococcal and streptococcal soft tissue-skeletal infections (six cases), spontaneous peritonitis (two cases), and complicated urinary tract infections (nine cases). Bacteremia was present in three patients. Microbiological and clinical cures were achieved in all but one case, although three patients with urinary infection had recurrences 6 weeks posttherapy. The only failure occurred in a patient with pneumonia who had a Pseudomonas aeruginosa isolated from sputum with an initial minimal inhibitory concentration of 4 ,uglml, but after 9 days of therapy, a repeat isolate had a minimal inhibitory concentration of 32 ,ug/ml. The minimal inhibitory concentrations for the other isolates ranged from <0.6 to 8.0 ,ug/ml. The mean peak plasma level of ceftriaxone was 99.9 ,ug/ml, whereas ceftriaxone levels obtained 12 h after a dose had a mean of 37.3 ,ug/ml. The only side effects noted were drug fever in one patient, phlebitis in two patients, and thrombocytosis in four patients.
Cephalosporin antibiotics are widely used to treat serious infections because of the spectrum of activity and the relative safety compared with other types of antibiotics. Several newly developed cephalosporins have increased potency against Enterobacteriaceae while maintaining activity against streptococci and staphylococci. Ceftriaxone (Ro 13-9904) is a 2-aminothiazolyl methoxyimino cephalosporin which inhibits most gram-negative enteric bacilli and streptococci at concentrations of less than 1 ,ug/ml (3, 5, 12) . It has a potential advantage over other recently discovered P-lactam antibiotics because of a contrast in pharmacokinetics. Ceftriaxone has a serum half-life of 8 h compared with 1 to 3 h for cefotaxime, cefoperazone, moxalactam, and other investigative third-generation cephalosporins (10) . This prolonged serum half-life apparently is related to a high degree of protein binding and a different excretion pattern for ceftriaxone compared with the cephalosporins listed above (11, 16) . In an open trial, the safety and clinical and bacteriological efficacy of ceftriaxone therapy of serious bacterial infection at a dosage of 1.0 g twice a day were evaluated.
(This paper was presented in part at the 21st International Congress of Antimicrobial Agents and Chemotherapy, Chicago, Ill., November 6, 1981 ... Toxicity evaluation. Patients were monitored daily for signs of toxicity. Hematological, renal, and hepatic parameters were measured every 4 days during therapy and at the conclusion of therapy.
Sttical evaluation. Analysis of antibiotic levels was performed by a nonparametric test, the MannWhitney U test, with P < 0.05 regarded as significant.
RESULTS
A total of 25 infections were documented in the 23 patients enrolled. One patient received only three doses of ceftriaxone until the diagnosis of pneumonia was excluded by the finding of pulmonary infarction. Three patients had culture-proven infections which were considered to be of moderate severity and are not included in this report with regard to efficacy. They are included in description of safety and plasma concentrations of ceftriaxone. The characteristics of the remaining 19 patients with serious infections are shown in Table 1 . Underlying diseases which probably contributed to the infections were coexistent in 84% of the patients (Table 1) . Evaluable patients were treated with at least 11 doses of ceftriaxone and received 15 to 44 mg/kg per day. The infections treated, the bacteria isolated with susceptibility to ceftriaxone, and descriptions of the severity of the infections are listed in Table 1 ;88zz
The mean peak plasma concentration of ceftriaxone was 99.5 ,ug/ml, whereas levels obtained 12 h after a dose had a mean of 37.3 pug/ The only clinical failure was a patient with carcinoma of the lung who had a postobstructive pneumonia. His sputum Gram stain indicated a predominance of gram-negative bacilli, and culture revealed Pseudomonas aeruginosa. The initial isolate had an MIC of 4 jig/ml to ceftriaxone, but after 9 days of therapy with this agent, there was no improvement in either his respiratory symptoms, fever patterns, or chest radiograph, and P. aeruginosa was still isolated. The repeat isolate had an MIC of 32 ,ug/ml to ceftriaxone (Table 1) . After administration of gentamicin and ticarcillin, he became afebrile, but radiation therapy to the chest was required before radiographic improvement was noted.
Organisms were eliminated at completion of therapy in all cases except for the P. aeruginosa described above (Table 1) . One patient with pyelonephritis and one patient with lower urinary tract infection had symptomatic lower tract infection with a different organism isolated from the urine 6 weeks after ceftriaxone therapy. The patient with the ureteral sphincterotomy had Providentia rettgeri isolated in his urine again 6 weeks after therapy, even though he was asymptomatic with the relapse. One patient with Klebsiella peritonitis was clinically cured, but 3 weeks later had a second episode of peritonitis with enterococcus isolated from the blood and peritoneal fluid. The patient with systemic lupus erythematosus had another staphylococcal abscess at another site requiring treatment 8 weeks after completion of ceftriaxone therapy. One diabetic patient with group B streptococcal osteomyelitis had recurrence of pain, drainage, and fever within 6 weeks of completion of therapy. A Proteus species was isolated from a deep wound culture, and amputation of his foot was needed for cure. Certain organisms were isolated during therapy (Table 3 ). These were considered to be colonization rather than infection, because in each situation there were no signs or symptoms of infection in contrast to when ceftriaxone therapy was begun.
Adverse effects of ceftriaxone were minimal (Table 4 ) but included two episodes of thrombophlebitis and one episode of diarrhea. The diarrhea was most likely due to lactose intolerance, since it resolved when milk products were withheld while the patient continued to receive ceftriaxone. One patient was considered to have drug fever and was the only subject in whom the drug was stopped for possible toxicity. She, however, continued to have fever on gentamicin therapy. This patient died progressive liver failure due to alcoholic hepatitis. None of the other patients died during the 6 weeks after therapy.
Of interest was that four patients had a marked increase in platelet count observed on either day 4 or day 8 of therapy ( (14) . Group B streptococci is uniformly susceptible to ceftriaxone (9) Thrombocytosis has been an infrequently recognized condition associated with cephalosporin therapy (10) . Four of the patients studied had a marked increase in platelet count within 8 days of starting the antibiotic, and two other patients had a similar but milder increase. Although ceftriaxone is a possible cause, it is reasonable to assume that the thrombocytosis observed was in response to severe infection and not the drug. In a double-blinded randomized comparison of cefamandole and penicillin in serious infection, both agents were associated with the same magnitude of thrombocytosis (10) .
Colonization with organisms that were relatively resistant to ceftriaxone occurred in some of this group of patients (Table 3) , and one patient had enterococcal sepsis and peritonitis 3 weeks after being cured of Klebsiella peritonitis. The only failure in this series was a man with pneumonia due to P. aeruginosa which, although originally susceptible to ceftriaxone, was persistently isolated in the sputum. The poor drainage associated with bronchial obstruction added to the difficulty in treatment, but the susceptibility to ceftriaxone decreased eightfold while the patient was on therapy (Table 1) . Although not studied in this patient, selection of resistant organisms from an original heterosusceptible population has been described in similar situations with other new 3-lactam antibiotics (8, 15 ).
Ceftriaxone appears to be a safe and effective antibiotic for serious infection in a twice-daily regimen. Seriously ill patients were found to respond favorably to ceftriaxone. This study did not examine patients with neutropenia and included only one patient with a moderately susceptible organism, P. aeruginosa. However, ceftriaxone was responsible for curing infection due to susceptible gram-negative bacilli, staphylococci, and ,B-hemolytic streptococci of both groups A and B in patients with underlying disease processes which contributed to the severity of the infections. Certain infections are commonly caused by a wide variety of microorganisms, including severe diabetic foot ulcers, pneumonia, peritonitis, or urinary tract infection. Seriously ill patients with these infections were found to respond favorably to. ceftriaxone. This study supports further investigation of this minimally toxic broad-spectrum antibiotic as a single agent for the treatment of certain serious bacterial infections when P. aeruginosa is not considered to be highly likely as the pathogen.
